AxoGen Company Profile (NASDAQ:AXGN)

About AxoGen (NASDAQ:AXGN)

AxoGen logoAxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AXGN
  • CUSIP: N/A
  • Web:
  • Market Cap: $646.52 million
  • Outstanding Shares: 33,240,000
Average Prices:
  • 50 Day Moving Avg: $18.43
  • 200 Day Moving Avg: $15.34
  • 52 Week Range: $7.65 - $19.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -243.13
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $50.02 million
  • Price / Sales: 12.93
  • Book Value: $0.34 per share
  • Price / Book: 57.21
  • EBITDA: ($8,050,000.00)
  • Net Margins: -27.50%
  • Return on Equity: -114.64%
  • Return on Assets: -27.71%
  • Debt-to-Equity Ratio: 1.80%
  • Current Ratio: 3.67%
  • Quick Ratio: 3.09%
  • Average Volume: 215,723 shs.
  • Beta: 0.29
  • Short Ratio: 5.8

Frequently Asked Questions for AxoGen (NASDAQ:AXGN)

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its earnings results on Wednesday, August, 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.02. The firm had revenue of $15.20 million for the quarter, compared to analyst estimates of $14.40 million. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The company's revenue was up 46.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.09) EPS. View AxoGen's Earnings History.

When will AxoGen make its next earnings announcement?

AxoGen is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for AxoGen.

Where is AxoGen's stock going? Where will AxoGen's stock price be in 2017?

6 brokers have issued 12 month price objectives for AxoGen's stock. Their forecasts range from $11.00 to $23.00. On average, they expect AxoGen's stock price to reach $17.40 in the next twelve months. View Analyst Ratings for AxoGen.

Who are some of AxoGen's key competitors?

How do I buy AxoGen stock?

Shares of AxoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AxoGen stock can currently be purchased for approximately $19.45.

MarketBeat Community Rating for AxoGen (NASDAQ AXGN)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  153
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AxoGen (NASDAQ:AXGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.40 (10.54% downside)
Consensus Price Target History for AxoGen (NASDAQ:AXGN)
Price Target History for AxoGen (NASDAQ:AXGN)
Analysts' Ratings History for AxoGen (NASDAQ:AXGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/30/2017Leerink SwannReiterated RatingOutperform$22.00 -> $23.00MediumView Rating Details
9/12/2017Roth CapitalReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
8/21/2017Cantor FitzgeraldReiterated RatingBuy$18.00LowView Rating Details
5/19/2017WedbushReiterated RatingOutperform$17.00 -> $14.00HighView Rating Details
11/22/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
11/22/2016Lake Street CapitalUpgradeHold -> Buy$9.00 -> $11.00N/AView Rating Details
(Data available from 10/16/2015 forward)


Earnings History for AxoGen (NASDAQ:AXGN)
Earnings by Quarter for AxoGen (NASDAQ:AXGN)
Earnings History by Quarter for AxoGen (NASDAQ AXGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.06)N/AView Earnings Details
8/2/2017Q2 2017($0.08)($0.06)$14.40 million$15.20 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.10)($0.11)$11.83 million$12.24 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.09)($0.10)$11.41 millionViewListenView Earnings Details
11/2/2016Q3 2016($0.08)($0.08)$11.21 million$11.21 millionViewN/AView Earnings Details
8/3/2016Q2($0.12)($0.09)$9.28 million$10.38 millionViewN/AView Earnings Details
11/5/2015Q3 2015($0.12)($0.11)$6.70 million$8.15 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.15)($0.13)$5.89 million$6.42 millionViewN/AView Earnings Details
5/5/2015Q1 2015($0.17)($0.16)$4.90 million$4.95 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.24)($0.19)$4.67 millionViewN/AView Earnings Details
8/4/2014Q2 2014($0.22)($0.21)$3.30 million$4.21 millionViewN/AView Earnings Details
4/30/2014Q1 2014($0.26)($0.24)$2.75 million$3.14 millionViewN/AView Earnings Details
3/6/2014($0.22)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AxoGen (NASDAQ:AXGN)
2017 EPS Consensus Estimate: ($0.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.12)($0.07)($0.10)
Q2 20173($0.06)($0.04)($0.05)
Q3 20174($0.10)($0.03)($0.06)
Q4 20173($0.14)($0.04)($0.08)
Q1 20182($0.10)$0.01($0.05)
Q2 20182($0.05)$0.03($0.01)
Q3 20181$0.04$0.04$0.04
(Data provided by Zacks Investment Research)


Dividend History for AxoGen (NASDAQ:AXGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for AxoGen (NASDAQ:AXGN)
Insider Ownership Percentage: 9.33%
Institutional Ownership Percentage: 66.47%
Insider Trades by Quarter for AxoGen (NASDAQ:AXGN)
Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)
Insider Trades by Quarter for AxoGen (NASDAQ:AXGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/11/2017Robert James RudeliusDirectorSell16,143$18.00$290,574.00View SEC Filing  
10/7/2016Amy Mcbride WendellDirectorBuy13,333$7.50$99,997.50View SEC Filing  
10/7/2016John P EngelsVPBuy4,000$7.50$30,000.00View SEC Filing  
10/7/2016Karen L ZaderejCEOBuy10,000$7.50$75,000.00View SEC Filing  
10/7/2016Peter J MarianiCFOBuy3,333$7.50$24,997.50View SEC Filing  
8/9/2016Joseph M MandatoDirectorSell149,618$8.54$1,277,737.72View SEC Filing  
8/8/2016Joseph M MandatoDirectorSell107,450$8.63$927,293.50View SEC Filing  
7/21/2016James E FlynnInsiderSell102,136$6.70$684,311.20View SEC Filing  
7/18/2016James E FlynnInsiderSell279,303$7.53$2,103,151.59View SEC Filing  
9/18/2015James E FlynnInsiderSell345,000$5.50$1,897,500.00View SEC Filing  
6/3/2015Joseph M MandatoDirectorBuy6,500$3.10$20,150.00View SEC Filing  
6/2/2015Lee Robert Johnston JrInsiderBuy5,000$3.06$15,300.00View SEC Filing  
4/8/2015James E FlynnInsiderSell144,385$3.25$469,251.25View SEC Filing  
12/10/2014Lee Robert Johnston JrCFOBuy10,000$3.06$30,600.00View SEC Filing  
8/12/2014Mark Stephen GoldDirectorBuy20,000$2.29$45,800.00View SEC Filing  
8/8/2014Mark Stephen GoldDirectorBuy11,000$2.31$25,410.00View SEC Filing  
6/6/2014Lee Robert Johnston JrCFOBuy10,000$2.58$25,800.00View SEC Filing  
6/3/2014Gregory Gene FreitagCFOBuy5,200$2.45$12,740.00View SEC Filing  
6/3/2014Karen L ZaderejCEOBuy5,000$2.43$12,150.00View SEC Filing  
5/20/2014Jill F SchiaparelliSVPBuy2,000$2.63$5,260.00View SEC Filing  
5/12/2014Karen L ZaderejCEOBuy5,000$2.70$13,500.00View SEC Filing  
5/7/2014Mark Stephen GoldDirectorBuy1,977$2.60$5,140.20View SEC Filing  
3/13/2014Karen L ZaderejCEOBuy1,500$3.49$5,235.00View SEC Filing  
8/29/2013Shawn F MccarreySVPBuy25,000$3.21$80,250.00View SEC Filing  
8/24/2013Shawn F MccarreySVPBuy5,000$3.00$15,000.00View SEC Filing  
8/14/2013Jill F SchiaparelliSVPBuy5,000$3.00$15,000.00View SEC Filing  
8/14/2013John Frederick HarperDirectorBuy66,666$3.00$199,998.00View SEC Filing  
8/14/2013Karen L ZaderejCEOBuy8,334$3.00$25,002.00View SEC Filing  
12/4/2012Jill F SchiaparelliSVPBuy2,000$2.55$5,100.00View SEC Filing  
11/29/2012Jill F SchiaparelliSVPBuy1,000$2.70$2,700.00View SEC Filing  
11/15/2012Jill F SchiaparelliSVPBuy2,750$2.56$7,040.00View SEC Filing  
10/1/2012John Frederick HarperDirectorBuy86,557$3.61$312,470.77View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AxoGen (NASDAQ:AXGN)
Latest Headlines for AxoGen (NASDAQ:AXGN)
DateHeadline logoETFs with exposure to AxoGen, Inc. : October 13, 2017 - October 13 at 4:54 PM logoNotable ETF Outflow Detected - DWAS, CORT, CBM, AXGN - October 10 at 5:35 PM logoAxoGen, Inc. (AXGN) Receives Average Rating of "Buy" from Brokerages - October 8 at 6:50 AM logoAxoGen, Inc. (AXGN) Expected to Post Quarterly Sales of $15.58 Million - October 6 at 4:48 AM logo-$0.08 Earnings Per Share Expected for AxoGen, Inc. (AXGN) This Quarter - October 4 at 6:26 PM logoAxoGen to Participate at 99th Annual American Association of Oral and Maxillofacial Surgeons Meeting - October 2 at 4:12 PM logoETFs with exposure to AxoGen, Inc. : October 2, 2017 - October 2 at 4:12 PM logoAxoGen, Inc. (AXGN) Given "Outperform" Rating at Leerink Swann - September 30 at 1:38 PM logoETFs with exposure to AxoGen, Inc. : September 22, 2017 - September 22 at 12:56 PM logoAxoGen, Inc. (AXGN) Receives Average Recommendation of "Buy" from Brokerages - September 13 at 6:38 AM logoRobert James Rudelius Sells 16,143 Shares of AxoGen, Inc. (AXGN) Stock - September 12 at 7:52 PM logoAxoGen, Inc. (AXGN) Stock Rating Reaffirmed by Roth Capital - September 12 at 9:30 AM logoETFs with exposure to AxoGen, Inc. : September 12, 2017 - September 11 at 9:51 PM logoAxoGen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference - September 11 at 4:49 PM logoAxoGen, Inc. :AXGN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 - September 8 at 9:41 PM logoAxoGen, Inc. (AXGN) Expected to Post Earnings of -$0.08 Per Share - August 28 at 12:24 PM logoAxoGen to Participate at 72nd Annual American Society for Surgery of the Hand Meeting - August 24 at 4:20 PM logoCantor Fitzgerald Reiterates "Buy" Rating for AxoGen, Inc. (AXGN) - August 21 at 8:28 PM logoAxoGen (AXGN): Key Points From Non Deal Roadshow - Cantor - August 21 at 4:16 PM logoAxoGen, Inc. (AXGN) Given Average Recommendation of "Buy" by Analysts - August 19 at 6:50 AM logoAxoGen, Inc. breached its 50 day moving average in a Bullish Manner : AXGN-US : August 15, 2017 - August 15 at 5:12 PM logoFinancial Comparison: Medtronic PLC (MDT) vs. AxoGen (AXGN) - August 15 at 12:38 PM logoAxoGen, Inc. (NASDAQ:AXGN) Expected to Announce Quarterly Sales of $15.58 Million - August 12 at 7:22 PM logoAxoGen, Inc. – Value Analysis (NASDAQ:AXGN) : August 11, 2017 - August 11 at 9:45 PM logoFY2017 EPS Estimates for AxoGen, Inc. Raised by Cantor Fitzgerald (NASDAQ:AXGN) - August 10 at 1:50 PM logo Analysts Expect AxoGen, Inc. (NASDAQ:AXGN) Will Announce Earnings of -$0.08 Per Share - August 10 at 8:06 AM logoQ3 2017 Earnings Estimate for AxoGen, Inc. Issued By Wedbush (AXGN) - August 7 at 8:09 AM logoQ3 2017 EPS Estimates for AxoGen, Inc. (AXGN) Reduced by Analyst - August 7 at 8:08 AM logoAxoGen, Inc. (AXGN) Forecasted to Post FY2019 Earnings of $0.16 Per Share - August 4 at 7:40 PM logoEdited Transcript of AXGN earnings conference call or presentation 2-Aug-17 8:30pm GMT - August 3 at 5:41 PM logoAxoGen, Inc. (AXGN) Releases Earnings Results, Beats Expectations By $0.02 EPS - August 3 at 3:38 PM logoAxoGen reports 2Q loss - August 2 at 10:02 PM logoAxoGen, Inc. Reports 2017 Second Quarter Financial Results - August 2 at 5:00 PM logoAxoGen, Inc. to Present at the Wedbush PacGrow Healthcare Conference - July 31 at 4:21 PM logoComparing Medtronic PLC (MDT) & AxoGen (AXGN) - July 29 at 2:09 PM logoAxoGen, Inc. breached its 50 day moving average in a Bearish Manner : AXGN-US : July 28, 2017 - July 28 at 5:38 PM logoAxoGen (AXGN) versus Integer Holdings (ITGR) Head to Head Survey - July 27 at 6:38 PM logoAxoGen, Inc. (AXGN) Set to Announce Quarterly Earnings on Wednesday - July 26 at 7:56 AM logoAxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of "Buy" by Brokerages - July 25 at 8:24 AM logo Analysts Anticipate AxoGen, Inc. (NASDAQ:AXGN) to Post -$0.08 EPS - July 20 at 10:18 PM logoAxoGen, Inc. Discloses Terms of Recent Equity Award - July 20 at 5:44 PM logoGlobus Medical (GMED) & AxoGen (NASDAQ:AXGN) Critical Review - July 20 at 5:21 PM logoAxoGen, Inc. to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, - July 19 at 5:29 PM logoAxoGen, Inc. to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 2, 2017 - July 19 at 5:29 PM logoInteger Holdings (ITGR) & AxoGen (NASDAQ:AXGN) Head to Head Analysis - July 16 at 12:26 PM logoComparing Sunshine Heart (SSH) & AxoGen (NASDAQ:AXGN) - July 16 at 12:28 AM logoReviewing Sunshine Heart (SSH) and AxoGen (NASDAQ:AXGN) - July 15 at 10:04 PM logoReviewing Globus Medical (GMED) and AxoGen (NASDAQ:AXGN) - July 15 at 8:07 AM logoAxoGen, Inc. (NASDAQ:AXGN) Forecasted to Earn FY2017 Earnings of ($0.30) Per Share - July 6 at 9:38 AM logoAxoGen (AXGN) Presents at JMP Securities Life Sciences Conference 2017 - Slideshow - June 22 at 3:52 PM



AxoGen (AXGN) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.